Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 7Phase 3 6Phase 1/2 5Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2

Interventions

Eating 5Standard of Care 4Radiofrequency Ablation 4Exercise 4Surgical Procedures, Operative 3Radiosurgery 3Endoscopic Mucosal Resection 3Adrenalectomy 3lutetium Lu 177 dotatate 2Yoga 2Saline Solution 2Robotic Surgical Procedures 2Resistance Training 2Proton Therapy 2Propofol 2Palliative Care 2Octreotide 2Magnetic Resonance Imaging 2Lutetium-177 2Liquid Biopsy 2Interviews as Topic 2Hydrocortisone 2Diet, Mediterranean 2Diet 2Desflurane 2Data Collection 2Conversion to Open Surgery 2Control Groups 2Calcium 23-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × lutetium Lu 177 dotatate × Endocrine × Clear all
NCT02743741 2025-12-03

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

University Health Network, Toronto

Phase NA Active not recruiting
195 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05513469 2023-04-07

Radio-Marker

Erasmus Medical Center

Phase NA Unknown
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡